Real-time enrollment status for this neurofibromatosis type 2 clinical trial
Current Status
Terminated
Checked: March 2, 2026 at 3:23 PM UTC
| NCT Number | NCT05130866 |
| Recruiting Status | Terminated |
| Condition | Neurofibromatosis Type 2 |
| Phase | Clinical Trial |
| Target Enrollment | 92 participants |
| Active Locations | 14 sites in the US |
| Sponsor | Recursion Pharmaceuticals Inc. |
| Last Updated on CT.gov | October 7, 2025 (Oct 7, 2025) |
As of March 2, 2026: Clinical trial NCT05130866 is currently terminated participants. This clinical trial study for neurofibromatosis type 2 is not currently accepting new participants at 14 locations across the United States. The study is sponsored by Recursion Pharmaceuticals Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
No, NCT05130866 is currently terminated. The study may resume recruiting in the future.
This trial is recruiting at 14 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT05130866 was last updated Oct 7, 2025 (October 7, 2025). HelloStudys verifies this status automatically.